The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
EHA 2024: Topline findings of the TUD-APOLLO-064 trial and their potential clinical implications
Featured:
Uwe PlatzbeckerDuring the European Hematology Association (EHA) 2024 Hybrid Congress, the AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, What were the topline findings of the TUD-APOLLO-064 trial and their potential clinical implications?
EHA 2024: Topline findings of the TUD-APOLLO-064 trial and their potential clinical implications
Professor Platzbecker shares the study design and latest data from the TUD-APOLLO-064 trial of arsenic trioxide combined with all-trans retinoic acid (ATRA-ATO) and idarubicin vs standard ATRA and anthracycline-based chemotherapy (ATRA-CHT) for the treatment of newly diagnosed, high-risk acute promyelocytic leukemia (APL). Platzbecker discusses the promising event-free survival data favoring the novel combination, without an increase in toxicities or mortality compared with the comparator arm. Platzbecker closes by providing his insight on how these data may influence the future treatment paradigm for patients with high-risk APL.
Key data and learnings from Professor Platzbecker’s presentation at EHA 2024 include1:
-
The primary endpoint, of two-year event free survival (EFS), was met with an EFS rate of 88% in the ATRA-ATO cohort and 70% for ATRA-CHT (p = 0.02).
-
Five-year overall survival was higher in the ATRA-ATO cohort at 93% versus 82% in the ATRA-CHT cohort (p = 0.17).
-
Two-year incidence of relapse was significantly higher in patients treated with ATRA-CHT at 14% compared with 1.6% for ATRA-ATO (p = 0.011).
-
The incidence of complete remission (CR) or CR with incomplete recovery was not significantly different between the two cohorts (it was numerically higher in the ATRA-ATO cohort at 93% versus 90% with ATRA-CHT (p = 0.654)).
-
There was no increased risk of early mortality with the novel ATRA-ATO regimen.
-
Data presented support the implementation of the ATRA-ATO regimen as a first-line therapy in high-risk APL.
References
